3-环丙基吡啶1-氧化物 | 188918-73-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-环丙基吡啶1-氧化物
• 英文名称: 3-cyclopropylpyridineloxide
• 英文别名: 3-Cyclopropylpyridine 1-oxide；3-cyclopropyl-1-oxidopyridin-1-ium
• CAS: 188918-73-2
• 化学式: C₈H₉NO
• 分子量: 135.166
• InChiKey: LBZYCFVOGHXGIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  25.5
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-环丙基吡啶1-氧化物 、 三甲基氰硅烷 在 二甲氨基甲酰氯 、 potassium carbonate 作用下， 以 氯仿 、 水 为溶剂， 生成 3-环丙基吡啶-2-甲腈
  参考文献：
  名称：

  EP1790650

  摘要：

  公开号：
• 作为产物：
  描述：

  3-环丙基吡啶 在 双氧水 、 溶剂黄146 作用下， 以 水 为溶剂， 生成 3-环丙基吡啶1-氧化物
  参考文献：
  名称：

  EP1790650

  摘要：

  公开号：

文献信息

• Novel Substituted Imidazole Derivative
  申请人：Kawamura Mikako

  公开号：US20080070894A1

  公开（公告）日：2008-03-20

  The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X 1 , X 2 , X 3 , and X 4 , which may be identical or different, are each C or N, provided that none to two of X 1 , X 2 , X 3 , and X 4 is/are N; Y is CH or N; R 1 , R 1 ′, R 2 , R 2 ′, R 3 , R 3 ′, R 4 , and R 4 ′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R 5 is a hydrogen atom or a methyl group; R 6 and R 7 , which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R 8 and R 8 ′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R 9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.

  本发明涉及一种由式[I]表示的化合物或其药学上可接受的盐或酯：其中，X1、X2、X3和X4可以相同也可以不同，分别为C或N，但是X1、X2、X3和X4中至少有一个或最多两个是N；Y为CH或N；R1、R1'、R2、R2'、R3、R3'、R4和R4'可以相同也可以不同，分别为氢原子、低碳基或类似物；R5为氢原子或甲基基团；R6和R7可以相同也可以不同，分别为氢原子、低碳基或类似物；R8和R8'可以相同也可以不同，分别为氢原子、低碳基或类似物；R9为取代的芳基或杂环基；n为1到3的整数。本发明还涉及一种PLK1抑制剂或含有该化合物的抗癌剂。
• Substituted imidazole derivative
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07718801B2

  公开（公告）日：2010-05-18

  The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1′, R2, R2′, R3, R3′, R4, and R4′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.

  本发明涉及一种由式[I]表示的化合物或其药学上可接受的盐或酯：其中，X1、X2、X3和X4可以相同或不同，每个为C或N，但X1、X2、X3和X4中的任意一个到两个不能是N；Y为CH或N；R1、R1'、R2、R2'、R3、R3'、R4和R4'可以相同或不同，每个为氢原子、低碳基或类似物；R5为氢原子或甲基基团；R6和R7可以相同或不同，每个为氢原子、低碳基或类似物；R8和R8'可以相同或不同，每个为氢原子、低碳基或类似物；R9为取代的芳基或杂芳基；n为1到3的整数；以及包含该化合物的PLK1抑制剂或抗癌药物。
• Inhibitors of HIV reverse transcriptase
  申请人：MERCK & CO. INC.

  公开号：EP0462800A2

  公开（公告）日：1991-12-27

  Novel pyridones inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by IV are also described.

  新型吡啶酮类药物可抑制艾滋病病毒逆转录酶，可用于预防或治疗艾滋病病毒感染和治疗艾滋病，可作为化合物、药学上可接受的盐、药物组合成分，无论是否与其他抗病毒药、抗感染药、免疫调节剂、抗生素或疫苗联合使用。还描述了治疗艾滋病的方法和预防或治疗 IV 感染的方法。
• NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1790650A1

  公开（公告）日：2007-05-30

  The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1', R2, R2', R3, R3', R4, and R4', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.

  本发明涉及一种由式[I]代表的化合物或其药学上可接受的盐或酯： 其中 X1、X2、X3和X4（可以相同或不同）各自是C或N，条件是X1、X2、X3和X4中没有一个至两个是/是N； Y 是 CH 或 N； R1、R1'、R2、R2'、R3、R3'、R4 和 R4'（可以相同或不同）各自是氢原子、低级烷基或类似物； R5 是氢原子或甲基； R6 和 R7 可以相同或不同，各自为氢原子、低级烷基或类似物； R8 和 R8'可以相同或不同，各自为氢原子、低级烷基或类似物； R9 是芳基或杂芳基，可被取代；以及 n 是 1 至 3 的整数、 以及 PLK1 抑制剂或含有相同成分的抗癌剂。
• 2-PYRIDONE COMPOUNDS
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：EP2508513A1

  公开（公告）日：2012-10-10

  2-Pyridone compounds represented by general formula [1], tautomers or stereoisomer thereof, pharmaceutically acceptable salts of the same, or solvates thereof have excellent GK-activating activity and therefore are useful as drugs. In general formula [1], A is a benzene ring or a pyridine ring; X is a structure represented by general formula [3]; V is a single bond or lower alkylene; W is a single bond, an ether linkage, or lower alkylene (which may contain an ether linkage).

  通式[1]所代表的 2-吡啶酮化合物、其同系物或立体异构体、其药学上可接受的盐或其溶液具有极佳的 GK 活性，因此可用作药物。在通式[1]中，A 是苯环或吡啶环；X 是通式[3]所代表的结构；V 是单键或低级亚烷基；W 是单键、醚键或低级亚烷基（可含有醚键）。